Clinical practice update: Prioritizing fidaxomicin for C. difficile in IBD
-
May 29
Update urges early testing, continued immunosuppression, and microbiome-based therapies to reduce recurrent infection in patients with inflammatory bowel disease.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Clinical practice update: Prioritizing fidaxomicin for C. difficile in IBD
-
by Doug Brunk
Update urges early testing, continued immunosuppression, and microbiome-based therapies to reduce recurrent infection in patients with inflammatory bowel disease.
HelPSCore may predict long-term PSC risk
-
by Doug Brunk
New dynamic model may outperform existing prognostic tools in identifying patients at highest risk for liver transplantation, hepatobiliary cancer, or liver-related death.
Endoscopic drug depots for chronic GI Disease: A conversation with Edulis Therapeutics
-
by Vasili Kalas, MD, PhD
"The drug-eluting stent of the GI world." How the team at Edulis is turning the endoscope into a delivery platform for chronic GI disease.
FDA approves first treatment for chronic HDV
-
by Doug Brunk
Phase 3 trial showed sustained viral suppression and alanine aminotransferase normalization in nearly half of treated patients.
Targeted screening may catch pancreatic cancer early enough to improve survival
-
by Doug Brunk
New-onset diabetes, genetic risk, and imaging advances may improve early detection and survival for patients at high risk.
